Zacks Investment Research upgraded shares of NATL RESEARCH (NRCI) from NEUTRAL to OUTPERFORM on August 17, 2012, with a target price of $55.30.
National Research Corporation is a leading provider of ongoing survey-based performance measurement, analysis and tracking services to the healthcare industry. The company addresses the growing need of healthcare providers and payers to measure the care outcomes, specifically satisfaction and health status, of their patients and/or members. The company's primary types of information services are renewable performance tracking services, custom research and a renewable syndicated service.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on NATL RESEARCH (NRCI),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment